Safety and Pharmacokinetic Evaluation of PTI5803 in Patients with Epilepsy

The primary objective of this study is the **evaluation of safety** and pharmacokinetic parameters of the PTI5803 product in individuals diagnosed with **epilepsy**. This objective is clinically relevant as it aims to determine the safety profile and absorption, distribution, metabolism, and excretion characteristics of PTI5803, which are critical for assessing its potential therapeutic use and ensuring patient safety. No secondary objectives are provided in the available data.

The clinical trial involves participants diagnosed with **epilepsy**. The study population includes both male and female subjects, with an age range categorized under code "3," which typically represents adults. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants. Participants were selected without specific mention of lifestyle considerations such as diet, physical activity, or habits. The sponsor has not disclosed key inclusion or exclusion criteria for this study.

The clinical trial is designed to evaluate the **safety** and pharmacokinetic parameters of the investigational product PTI5803 in individuals diagnosed with **epilepsy**. This study is structured as a Phase 3 trial, which typically involves a larger participant group to confirm efficacy, monitor side effects, and collect information that will allow the investigational product to be used safely. The trial is expected to commence recruitment on July 29, 2024, and is projected to conclude by October 29, 2024. The trial will employ a randomized, double-blind, controlled design to ensure the reliability and validity of the results.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation to ensure participants meet the necessary inclusion criteria and do not fall under any exclusion criteria. Following successful screening, participants will be randomly assigned to either the investigational product group or a control group. Throughout the trial, participants will attend scheduled follow-up visits to monitor their health status, assess the pharmacokinetic profile of PTI5803, and document any adverse events. These visits are crucial for collecting data on the primary and secondary endpoints of the study.

The expected duration of participant involvement in the trial will align with the overall trial timeline, from the recruitment start date to the estimated end date. However, certain conditions may necessitate early termination from the study, such as the occurrence of significant adverse events, withdrawal of consent, or non-compliance with the study protocol. The trial will conclude with an end-of-study visit, where final assessments will be conducted to gather comprehensive data on the investigational product's safety and efficacy. This visit will also provide an opportunity to discuss any post-trial follow-up care that may be required.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on July 29, 2024, with an estimated completion date of October 29, 2024. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology to measure, collect, and analyze these efficacy parameters, adhering to the standards expected in a Phase 3 clinical trial. The trial's design and execution will ensure that the efficacy assessments are conducted systematically and objectively, in line with clinical trial protocols.